ISE:RYA
ISE:RYAAirlines

Ryanair Holdings (ISE:RYA) Valuation Check After Recent Share Price Pullback

What Ryanair’s Recent Share Performance Tells You Ryanair Holdings (ISE:RYA) has been on investors’ radar after a recent pullback, with the stock showing a 1 day return of around a 1% decline and a 5% decline over the past week. Over the past month, Ryanair has recorded roughly a 4% decline, while the past 3 months show a gain of about 12%. Year to date, the stock is down around 5%, yet the 1 year total return sits near 58%. Against this share performance backdrop, Ryanair’s latest reported...
ISE:RYA
ISE:RYAAirlines

Assessing Ryanair (ISE:RYA) After A 58.3% Year Return In Low Cost Travel Focus

If you are wondering whether Ryanair Holdings is still good value after a strong run, you are in the right place. This article focuses squarely on what you might be paying for each euro of fundamentals. The share price recently closed at €29.10, with returns of 3.2% over the last 30 days and 58.3% over 1 year, while the year to date return sits at a 2.0% decline and the 3 year and 5 year returns are 107.4% and 92.3% respectively. Recent developments around Ryanair Holdings have kept investor...
ISE:IRES
ISE:IRESResidential REITs

European Small Caps With Insider Action Highlighting Undervalued Opportunities

As the pan-European STOXX Europe 600 Index reaches new heights, buoyed by an improving economic backdrop and marking its strongest yearly performance since 2021, investors are increasingly focusing on small-cap opportunities within this dynamic market landscape. In such a thriving environment, identifying stocks with strong fundamentals and insider activity can highlight potential undervalued opportunities in the European small-cap sector.
ISE:UPR
ISE:UPRHealthcare

Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?

Zevra Therapeutics announced that it has entered into an exclusive expanded access distribution agreement with Ireland-based Uniphar, enabling Niemann-Pick Disease Type C patients in select territories outside Europe to obtain reimbursed named-patient supply of MIPLYFFA, the only approved therapy that targets the underlying pathology of this ultra-rare condition. The deal strengthens Uniphar’s position as a specialist partner for complex rare-disease logistics, highlighting its capabilities...
ISE:RYA
ISE:RYAAirlines

Should Ryanair’s Robust December Traffic and Load Factors Shape a Rethink for (ISE:RYA) Investors?

Ryanair Holdings plc has reported its December 2025 traffic results, with 14.5 million guests for the month and 206.5 million year to date, while maintaining load factors of 92% and 94% respectively, broadly in line with the prior year. The combination of rising guest numbers and consistently high load factors points to sustained demand for Ryanair’s network and capacity deployment. We will now examine how this continued growth in guest numbers shapes Ryanair’s investment narrative and...
ISE:PTSB
ISE:PTSBBanks

How Is Permanent TSB's (ISE:PTSB) Recent Lending Activity Shaping Its Earnings Prospects?

Permanent TSB Group Holdings plc recently released its Q3 2025 sales and trading statement during a scheduled call on October 30, 2025, offering investors updated insights into its operational performance for the quarter. This quarterly update provided stakeholders with key details about recent lending activity, cost management progress, and broader trends influencing the bank's outlook in Ireland's evolving financial landscape. We'll examine how the latest quarterly trading statement update...